Abstract
Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic Non–small Cell Lung Cancer Without EGFR or ALK Mutations is Superior to Chemotherapy Alone
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have